- Home
- LONA vs LPAA Comparison
LONA vs LPAA Comparison
Compare LONA & LPAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LONA | LPAA |
|---|---|---|
| Founded | 2011 | 2024 |
| Country | United States | United States |
| Employees | 19 | 2 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.5M | 80.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LONA | LPAA |
|---|---|---|
| Price | $7.50 | $10.75 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 29.4K | ★ 48.2K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.21 | $10.39 |
| 52 Week High | $14.21 | $11.67 |
Technical Indicators
Market Signals| Indicator | LONA | LPAA |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 44.28 |
| Support Level | $6.86 | $10.47 |
| Resistance Level | $9.78 | $11.19 |
| Average True Range (ATR) | 0.47 | 0.11 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 76.56 | 0.00 |
Price Performance
Historical ComparisonAbout LONA LeonaBio Inc. Common Stock
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
About LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.